Trial data checked Oct 17, 2026
Retatrutide vs Tirzepatide: What the Trials Show in 2026
Retatrutide led to more weight loss than tirzepatide in separate trials, but it is not FDA-approved and has no launch date. Tirzepatide (Zepbound) is available now from $299/mo.
- Retatrutide not FDA-approved
- Head-to-head TRIUMPH-5 running
- Both weekly injections
- Both from Lilly
We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure
Chia Health
Our #1 pick for GLP-1 weight loss online
- One monthly price: clinician, medication and free shipping included
- Semaglutide or tirzepatide, as a weekly injection or a daily tablet
- No insurance needed; HSA/FSA and Klarna accepted
Compounded medications, not FDA-approved. Prices checked Nov 17, 2026. Advertiser Disclosure
$212.89 first month, then $349/mo
6-month plan: $249/mo, paid upfront ($1,396.89 for the first 6 months). Microdose: $109.19 first month, then $179/mo.
01 At a glance
Retatrutide vs Tirzepatide at a Glance
Both drugs come from Eli Lilly, and both are once-weekly injections. The difference that matters most today is legal status: one is sold in pharmacies, the other exists only inside clinical trials.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Maker | Eli Lilly | Eli Lilly |
| Receptors | GIP + GLP-1 + glucagon | GIP + GLP-1 |
| FDA status | Investigational. Lilly plans to file its application in Q1 2027 | Approved: Mounjaro (type 2 diabetes) May 2022, Zepbound (weight) Nov 2023 |
| Form | Weekly injection (in trials) | Weekly injection, single-dose vial or KwikPen |
| Doses | 4, 9 and 12 mg studied in trials | 2.5 to 15 mg on the FDA label |
| Brand names | None | Zepbound, Mounjaro |
| Legal access | Clinical trial or Lilly expanded access only | Retail pharmacy, LillyDirect, telehealth prescribers |
| Compounding | Not allowed under federal law (FDA) | Compounded copies exist; they are not FDA-approved |
Full background on the investigational drug: retatrutide FDA status and trials. The two tirzepatide brands explained: Mounjaro and Zepbound.
02 Mechanism
Tirzepatide vs Retatrutide: How They Work
"GLP-3" is an internet nickname for retatrutide, not a real hormone or receptor. People use it because retatrutide is a triple agonist (also called "triple G"), one step beyond tirzepatide's two receptors. There is no GLP-3 in the body. More on the name and the sellers using it: what GLP-3 means.
The glucagon part is the new piece, and it brings a new watch item. In the phase 2 trial published in NEJM in 2023, heart rate rose with dose and peaked around week 24 before easing. Background reading: how GLP-1 drugs work and is Zepbound a GLP-1.
03 Weight loss
Weight Loss: Retatrutide vs Tirzepatide Trial Results
Trials count weight loss two ways. The efficacy estimand assumes everyone stayed on the drug; the treatment-regimen estimand counts everyone randomized, including people who stopped.
Chart A: Efficacy estimand
Placebo 2.2% (TRIUMPH-1) and 2.4% (SURMOUNT-1).
Chart B: Treatment-regimen estimand
Placebo 3.9% (TRIUMPH-1) and 3.1% (SURMOUNT-1).
Chart C: With type 2 diabetes, efficacy estimand
Placebo 4.0% (TRIUMPH-2) and 3.3% (SURMOUNT-2).
Separate trials, different lengths (80 vs 72 weeks). Not head-to-head. Each chart uses one estimand only.
At the top doses, retatrutide is about 4 to 6 percentage points ahead depending on the estimand, but its trials ran 8 weeks longer. Lower retatrutide doses overlap with tirzepatide: 4 mg gave 19.0% and 9 mg gave 25.9% in TRIUMPH-1 (efficacy estimand). A subgroup with a BMI of 35 or higher that stayed on to week 104 reached 30.3% on 12 mg, which is why some headlines say "30%". For the TRIUMPH-2 detail, see our TRIUMPH-2 full results report.
04 Side effects
Side Effects Compared
| Adverse event | Retatrutide 12 mg (TRIUMPH-1) | Zepbound 5 to 15 mg (FDA label) |
|---|---|---|
| Nausea | 42.4% (placebo 14.8%) | 25 to 29% (placebo 8%) |
| Diarrhea | 32.0% (placebo 13.5%) | 19 to 23% (placebo 8%) |
| Constipation | 26.1% (placebo 10.9%) | 11 to 17% (placebo 5%) |
| Vomiting | 25.3% (placebo 4.8%) | 8 to 13% (placebo 2%) |
| Dysesthesia (odd skin sensations) | 12.5% (placebo 0.9%) | Not a listed common reaction |
| Stopped for side effects | 11.3% (placebo 4.9%) | 4.8 to 6.7% (placebo 3.4%) |
Stomach side effects lead on both drugs, and both are dose-related. Retatrutide 12 mg roughly doubled the vomiting rate of top-dose Zepbound in these separate trials, and more than 1 in 10 people stopped it. Only tirzepatide has a final FDA label, which carries a boxed warning for thyroid C-cell tumors; retatrutide's full safety profile is still under review. Our Zepbound side effects guide covers the label warnings in plain English.
Self-pay visit $129, insured visits typically $30 copay or less (PlushCare, Oct 2026).
05 Head to head
The Head-to-Head Trial: TRIUMPH-5
- Registered
NCT06662383: phase 3, randomized, double-blind, retatrutide vs tirzepatide in adults with obesity.
- Enrolled
About 800 participants (estimated). Status: active, not recruiting.
- Measures
Percent change in body weight at week 80.
- Nov 2026 (estimated)
Primary completion; study completion estimated Dec 2026.
TRIUMPH-5 is the first trial that puts the two drugs side by side with one protocol, one population and one estimand. Results are not public yet. When Lilly reports them, we will cover the numbers in GLP-1 news and update this page.
06 Availability
Cost and Availability
Retatrutide
No price, not on sale
- Not approved, and Lilly has announced no price.
- The FDA says retatrutide cannot be used in compounding under federal law.
- Vials sold online as "research use only" or "not for human consumption" are unapproved drugs; the FDA has sent warning letters to sellers and to telehealth companies marketing retatrutide.
- The only legal routes are a clinical trial or Lilly's expanded access program (see the next section).
Tirzepatide, Zepbound
$299 to $449/mo self-pay
- LillyDirect self-pay, vial or KwikPen: 2.5 mg $299, 5 mg $399, 7.5 to 15 mg $449 when you refill within 45 days (otherwise $499 for 7.5 mg, $699 for 10 to 15 mg).
- Savings card with commercial coverage: as little as $25 a month (expires Dec 31, 2026).
- Medicare GLP-1 Bridge: $50 a month for the KwikPen, Jul 1, 2026 to Dec 31, 2027, for eligible Part D members.
- Compounded tirzepatide is not FDA-approved. See compounded tirzepatide.
Prices as of Oct 2026 from zepbound.lilly.com and CMS; they can change. Telehealth programs add a membership on top: at Hers it is $149 a month after a $39 first month.
07 Decision
Should You Wait for Retatrutide?
- Timeline. Lilly plans to file in Q1 2027. With a standard FDA review of about a year, late 2027 is the earliest realistic US launch.
- Switching later. Starting an approved drug now does not rule out a change once retatrutide is approved. Your prescriber decides if and when.
- Cost of waiting. A year or more without treatment is a year of untreated weight-related risk, while Zepbound is available today from $299/mo.
- Expanded access is narrow. It is limited to adults with a BMI of 35 or higher despite the highest available dose of a weight drug, plus 2 or more serious obesity-related complications, on a physician's request.
- No self-sourcing. Any retatrutide outside a trial is an unapproved product of unknown content.
If you want to start now, the legal options for tirzepatide are a retail pharmacy prescription, LillyDirect, or a telehealth prescriber. We compare them in tirzepatide online.
Ro bills a membership ($39 first month, then $74 to $149/mo) plus Zepbound at LillyDirect self-pay prices (Oct 2026).
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or qualified health provider with any questions about a medical condition or medication. Never disregard professional medical advice or delay seeking it because of something you have read on this website.
08 FAQ
Retatrutide vs Tirzepatide FAQ
Is retatrutide better than tirzepatide?
Tirzepatide vs retatrutide: which has more side effects?
What is GLP-3 retatrutide?
Is retatrutide FDA approved?
Can I switch from tirzepatide to retatrutide?
Is there a head-to-head study of retatrutide vs tirzepatide?
How much does tirzepatide cost compared with retatrutide?
References
- Lilly's triple agonist retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1), May 21, 2026, Eli Lilly, 2026
- Lilly's triple agonist retatrutide delivered substantial weight loss and A1C reduction (TRIUMPH-2), Sep 29, 2026, Eli Lilly, 2026
- SURMOUNT-1 results (up to 22.5%, NEJM 2022), Eli Lilly, 2022
- SURMOUNT-2 results (up to 15.7%, Lancet 2023), Eli Lilly, 2023
- Zepbound (tirzepatide) prescribing information, revised Aug 2026, Eli Lilly / FDA, 2026
- Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial, New England Journal of Medicine, 2023
- TRIUMPH-5, NCT06662383, ClinicalTrials.gov, 2026
- Pre-approval Expanded Access of Retatrutide, NCT07629401, ClinicalTrials.gov, 2026
- FDA's concerns with unapproved GLP-1 drugs used for weight loss, updated Oct 1, 2026, U.S. Food and Drug Administration, 2026
- Zepbound coverage and savings (LillyDirect self-pay, savings card), Eli Lilly, 2026
- Medicare GLP-1 Bridge: information for Part D plans, Centers for Medicare & Medicaid Services, 2026